Women were less than half of the people tested for almost all of these common medicines.
PregnancyCommunity forum

NCT00461630

Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE

See it on ClinicalTrials.gov ↗

25,673 people

4,444 womenmiddle line = equal numbers21,229 men
Phase
PHASE3
Paid for by
University of Oxford
Finished
2012-10
Health conditions
Cardiovascular Disease, Peripheral Arterial Disease, Diabetes Mellitus, Coronary Heart Disease
Who could join
Anyone
Ages
50 Years – 80 Years
Average age
mean 64.9 years
Age 65+
49.6%
Weight (BMI)
Not reported
Pregnancy recorded
Not reported
Menopause recorded
Not reported
Results shown by sex
Not split by sex
Race
Not reported

Women left out

  • No kidney or liver problems

    Women with kidney or liver problems were turned away.

    “Definite history of chronic liver disease, or abnormal liver function (i.e. Alanine transaminase (ALT) \>1.5 times upper limit of normal (ULN). (Note: Patients with a history of acute hepatitis are eligible provided this ALT limit is not ex…”
  • No heart disease

    Women with heart disease, heart rhythm problems or a past heart attack were turned away.

    “Less than 3 months since presentation with acute myocardial infarction, coronary syndrome or stroke (but such patients may be entered later, if appropriate);”
  • No cancer

    Women with current or past cancer were turned away.

    “…lity to take trial treatments for the duration of the study (e.g. severe respiratory disease, history of cancer or evidence of spread within last 5 years other than non-melanoma skin cancer, or recent history of alcohol or substance misuse)”

Study titles and rules are shown in their original English.